159 related articles for article (PubMed ID: 19596885)
21. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.
Tisdale M; Alnadaf T; Cousens D
Antimicrob Agents Chemother; 1997 May; 41(5):1094-8. PubMed ID: 9145875
[TBL] [Abstract][Full Text] [Related]
22. Partial selective inhibition of HIV-1 reverse transcriptase and human DNA polymerases γ and β by thiated 3'-fluorothymidine analogue 5'-triphosphates.
Wińska P; Miazga A; Poznański J; Kulikowski T
Antiviral Res; 2010 Nov; 88(2):176-81. PubMed ID: 20739003
[TBL] [Abstract][Full Text] [Related]
23. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
24. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate.
Ray AS; Yang Z; Shi J; Hobbs A; Schinazi RF; Chu CK; Anderson KS
Biochemistry; 2002 Apr; 41(16):5150-62. PubMed ID: 11955063
[TBL] [Abstract][Full Text] [Related]
25. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.
Gu Z; Allard B; de Muys JM; Lippens J; Rando RF; Nguyen-Ba N; Ren C; McKenna P; Taylor DL; Bethell RC
Antimicrob Agents Chemother; 2006 Feb; 50(2):625-31. PubMed ID: 16436719
[TBL] [Abstract][Full Text] [Related]
26. [Suppression of the human immunodeficiency virus in cultured cells by 5'-phosphites of 3'-azido-2',3'-dideoxynucleosides].
Karamov EV; Lukashov VV; Tarusova NB; Kornilaeva GV; Rodova MA; Kukhanova MK; Kraevskiĭ AA
Mol Biol (Mosk); 1990; 24(6):1695-701. PubMed ID: 1710021
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
Borroto-Esoda K; Parkin N; Miller MD
Antivir Chem Chemother; 2007; 18(5):297-300. PubMed ID: 18046962
[TBL] [Abstract][Full Text] [Related]
28. Marked inhibitory activity of masked aryloxy aminoacyl phosphoramidate derivatives of dideoxynucleoside analogues against visna virus infection.
Balzarini J; Cahard D; Wedgwood O; Salgado A; Velázquez S; Yarnold CJ; De Clercq E; McGuigan C; Thormar H
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):296-302. PubMed ID: 9525429
[TBL] [Abstract][Full Text] [Related]
29. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
30. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
[TBL] [Abstract][Full Text] [Related]
31. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
32. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
[TBL] [Abstract][Full Text] [Related]
33. Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides.
Murakami K; Shirasaka T; Yoshioka H; Kojima E; Aoki S; Ford H; Driscoll JS; Kelley JA; Mitsuya H
J Med Chem; 1991 May; 34(5):1606-12. PubMed ID: 2033586
[TBL] [Abstract][Full Text] [Related]
34. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
[TBL] [Abstract][Full Text] [Related]
35. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
36. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
37. New nucleoside/nucleotide backbone options: a review of recent studies.
Ruane PJ; DeJesus E
J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S21-9. PubMed ID: 15319666
[TBL] [Abstract][Full Text] [Related]
38. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
[TBL] [Abstract][Full Text] [Related]
39. Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection.
Senanayake TH; Gorantla S; Makarov E; Lu Y; Warren G; Vinogradov SV
Mol Pharm; 2015 Dec; 12(12):4226-36. PubMed ID: 26565115
[TBL] [Abstract][Full Text] [Related]
40. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.
Nitanda T; Wang X; Kumamoto H; Haraguchi K; Tanaka H; Cheng YC; Baba M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3355-60. PubMed ID: 16048947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
